Cilostazol Verse Asprin for Vascular Dementia in Poststroke Patients With White Matter Lesions (CAVAD)

Trial Profile

Cilostazol Verse Asprin for Vascular Dementia in Poststroke Patients With White Matter Lesions (CAVAD)

Completed
Phase of Trial: Phase IV

Latest Information Update: 11 May 2015

At a glance

  • Drugs Cilostazol (Primary) ; Aspirin
  • Indications Embolism and thrombosis; Stroke; Vascular dementia
  • Focus Therapeutic Use
  • Acronyms CAVAD
  • Most Recent Events

    • 21 Jul 2011 Planned end date changed from 1 Jun 2010 to 1 Jun 2011 as reported by ClinicalTrials.gov.
    • 21 Jul 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 24 Feb 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top